As many Americans start the summer stressed about their physiques and health, there are important developments. Drug-makers report successful mid-stage trials for oral compounds that could soon join the injectable prescription medication to treat obesity that’s already on the market.
Dr. Jamy Ard, president-elect of The Obesity Society, says he believes oral obesity medications offer new options for those not comfortable with an injectable drug and for those who suffer adverse side effects from current offerings. He also believes more choices will lower prices for consumers.
“I think we’re at a watershed moment, this is really sort of an inflection point if you will, in thinking about the potential change in the landscape and how we conceptualize treatment of obesity. For the longest [time], a lot of the basic thinking about how we treat obesity was rooted in it was just a calorie imbalance…people were eating too much and exercising too little. As you know, that clearly has not worked,” says Dr. Ard.
He shares more insights on “Conversations on Health Care” with hosts Mark Masselli and Margaret Flinter.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Spotify | Android | Podchaser | TuneIn | RSS | More
Originally broadcast January 23, 2025 President Trump’s first days in office have resulted in a…
Originally broadcast August 22, 2023 As the year begins, some patients remain concerned about how…
Originally broadcast June 8, 2023 The World Health Organization has issued a statement expressing concern…
Originally broadcast January 2, 2025. Conversations on Health Care hopes the new year is off…
Originally broadcast December 26, 2024 Dr. Amit Sood is called the “Happiness Doctor” for a…
Originally broadcast December 20, 2024 Billionaires who dream of extending human life, including Elon Musk,…